WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced the presentation of three significant abstracts at the EORTC-NCI-AACR Symposium in Barcelona. These presentations, held from October 23-25, 2024, highlight their pioneering SMARCA Degrader Programs, which are geared towards developing advanced treatments for patients with high unmet needs.
Kris Vaddi, Ph.D., CEO of Prelude, expressed enthusiasm about the opportunity to share their progress, stating, “We are delighted to have this opportunity to share additional information from our SMARCA degrader programs to the scientific and medical communities.” Among the advancements is the Phase 1 trial of PRT3789, a selective SMARCA2 degrader, aimed at patients with SMARCA4 mutations, with a presentation scheduled for October 24 from 10:00 AM to 10:12 AM (CEST).
Additionally, Prelude is presenting the first preclinical data from their novel antibody drug conjugates (ADCs) program. This will be showcased in a poster session on October 24, from 9:00 AM to 5:30 PM (CEST), focusing on targeting tumor cells with a potent SMARCA2/4 degrader payload. This approach could potentially replace traditional chemotherapy payloads in ADCs, broadening treatment opportunities beyond just SMARCA4-mutated cancers.
With ongoing trials and a focus on innovative therapies, Prelude Therapeutics is poised to make significant contributions to cancer treatment, addressing high unmet needs with their groundbreaking research.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.